Cell potency is a cell's ability to differentiate into other cell types The more cell types a cell can differentiate into, the greater its potency. Potency is also described as the gene activation potential within a cell which like a continuum begins with totipotency to designate a cell with the most differentiation potential, pluripotency, multipotency, oligopotency and finally unipotency.
Totipotency (Lat. totipotentia, "ability for all [things]") is the ability of a single cell to divide and produce all of the differentiated cells in an organism. Spores and zygotes are examples of totipotent cells. In the spectrum of cell potency, totipotency is a form of pluripotency that represents the cell with the greatest differentiation potential.
It is possible for a fully differentiated cell to return to a state of totipotency. This conversion to totipotency is complex, not fully understood and the subject of recent research. Research in 2011 has shown that cells may differentiate not into a fully totipotent cell, but instead into a "complex cellular variation" of totipotency. Stem cells resembling totipotent blastomeres from 2-cell stage embryos can arise spontaneously in mouse embryonic stem cell cultures and also can be induced to arise more frequently in vitro through down-regulation of the chromatin assembly activity of CAF-1.
The human development model is one which can be used to describe how totipotent cells arise. Human development begins when a sperm fertilizes an egg and the resulting fertilized egg creates a single totipotent cell, a zygote. In the first hours after fertilization, this zygote divides into identical totipotent cells, which can later develop into any of the three germ layers of a human (endoderm, mesoderm, or ectoderm), or into cells of the placenta (cytotrophoblast or syncytiotrophoblast). After reaching a 16-cell stage, the totipotent cells of the morula differentiate into cells that will eventually become either the blastocyst's Inner cell mass or the outer trophoblasts. Approximately four days after fertilization and after several cycles of cell division, these totipotent cells begin to specialize. The inner cell mass, the source of embryonic stem cells, becomes pluripotent.
Research on Caenorhabditis elegans suggests that multiple mechanisms including RNA regulation may play a role in maintaining totipotency at different stages of development in some species. Work with zebrafish and mammals suggest a further interplay between miRNA and RNA-binding proteins (RBPs) in determining development differences.
In cell biology, pluripotency (Lat. pluripotentia, "ability for many [things]") refers to a stem cell that has the potential to differentiate into any of the three germ layers: endoderm (interior stomach lining, gastrointestinal tract, the lungs), mesoderm (muscle, bone, blood, urogenital), or ectoderm (epidermal tissues and nervous system). However, cell pluripotency is a continuum, ranging from the completely pluripotent (or totipotent) cell that can form every cell of the embryo proper, e.g., embryonic stem cells and iPSCs (see below), to the incompletely or partially pluripotent cell that can form cells of all three germ layers but that may not exhibit all the characteristics of completely pluripotent cells.
Induced pluripotent stem cells, commonly abbreviated as iPS cells or iPSCs, are a type of pluripotent stem cell artificially derived from a non-pluripotent cell, typically an adult somatic cell, by inducing a "forced" expression of certain genes and transcription factors. These transcription factors play a key role in determining the state of these cells and also highlights the fact that these somatic cells do preserve the same genetic information as early embryonic cells. The ability to induce cells into a pluripotent state was initially pioneered in 2006 using mouse fibroblasts and four transcription factors, Oct4, Sox2, Klf4 and c-Myc; this technique, called reprogramming, earned Shinya Yamanaka and John Gurdon the Nobel Prize in Physiology or Medicine 2012. This was then followed in 2007 by the successful induction of human iPSCs derived from human dermal fibroblasts using methods similar to those used for the induction of mouse cells. These induced cells exhibit similar traits to those of embryonic stem cells (ESCs) but do not require the use of embryos. Some of the similarities between ESCs and iPSCs include pluripotency, morphology, self-renewal ability, a trait that implies that they can divide and replicate indefinitely, and gene expression.
Epigenetic factors are also thought to be involved in the actual reprogramming of somatic cells in order to induce pluripotency. It has been theorized that certain epigenetic factors might actually work to clear the original somatic epigenetic marks in order to acquire the new epigenetic marks that are part of achieving a pluripotent state. Chromatin is also reorganized in iPSCs and becomes like that found in ESCs in that it is less condensed and therefore more accessible. Euchromatin modifications are also common which is also consistent with the state of euchromatin found in ESCs.
Due to their great similarity to ESCs, iPSCs have been of great interest to the medical and research community. iPSCs could potentially have the same therapeutic implications and applications as ESCs but without the controversial use of embryos in the process, a topic of great bioethical debate. In fact, the induced pluripotency of somatic cells into undifferentiated iPS cells was originally hailed as the end of the controversial use of embryonic stem cells. However, iPSCs were found to be potentially tumorigenic, and, despite advances, were never approved for clinical stage research in the United States. Setbacks such as low replication rates and early senescence have also been encountered when making iPSCs, hindering their use as ESCs replacements.
Additionally, it has been determined that the somatic expression of combined transcription factors can directly induce other defined somatic cell fates (transdifferentiation); researchers identified three neural-lineage-specific transcription factors that could directly convert mouse fibroblasts (skin cells) into fully functional neurons. This result challenges the terminal nature of cellular differentiation and the integrity of lineage commitment; and implies that with the proper tools, all cells are totipotent and may form all kinds of tissue.
Some of the possible medical and therapeutic uses for iPSCs derived from patients include their use in cell and tissue transplants without the risk of rejection that is commonly encountered. iPSCs can potentially replace animal models unsuitable as well as in vitro models used for disease research.
Recent findings with respect to epiblasts before and after implantation have produced proposals for classifying pluripotency into two distinct phases: "naive" and "primed". The baseline stem cells commonly used in science that are referred as Embryonic stem cells (ESCs) are derived from a pre-implantation epiblast; such epiblast is able to generate the entire fetus, and one epiblast cell is able to contribute to all cell lineages if injected into another blastocyst. On the other hand, several marked differences can be observed between the pre- and post-implantation epiblasts, such as their difference in morphology, in which the epiblast after implantation changes its morphology into a cup-like shape called the "egg cylinder" as well as chromosomal alteration in which one of the X-chromosomes undergoes random inactivation in the early stage of the egg cylinder, known as X-inactivation. During this development, the egg cylinder epiblast cells are systematically targeted by Fibroblast growth factors, Wnt signaling, and other inductive factors via the surrounding yolk sac and the trophoblast tissue, such that they become instructively specific according to the spatial organization. Another major difference that was observed, with respect to cell potency, is that post-implantation epiblast stem cells are unable to contribute to blastocyst chimeras, which distinguishes them from other known pluripotent stem cells. Cell lines derived from such post-implantation epiblasts are referred to as epiblast-derived stem cells which were first derived in laboratory in 2007; despite their nomenclature, that both ESCs and EpiSCs are derived from epiblasts, just at difference phases of development, and that pluripotency is still intact in the post-implantation epiblast, as demonstrated by the conserved expression of Nanog, Fut4, and Oct-4 in EpiSCs, until somitogenesis and can be reversed midway through induced expression of Oct-4.
Multipotency describes progenitor cells which have the gene activation potential to differentiate into discrete cell types. For example, a multipotent blood stem cell and this cell type can differentiate itself into several types of blood cell types like lymphocytes, monocytes, neutrophils, etc., but it is still ambiguous whether HSC possess the ability to differente into brain cells, bone cells or other non-blood cell types.
New research related to multipotent cells suggests that multipotent cells may be capable of conversion into unrelated cell types. In another case, human umbilical cord blood stem cells were converted into human neurons. Research is also focusing on converting multipotent cells into pluripotent cells.
Multipotent cells are found in many, but not all human cell types. Multipotent cells have been found in cord blood, adipose tissue, cardiac cells, bone marrow, and mesenchymal stem cells (MSCs) which are found in the third molar.
MSCs may prove to be a valuable source for stem cells from molars at 810 years of age, before adult dental calcification. MSCs can differentiate into osteoblasts, chondrocytes, and adipocytes.
In biology, oligopotency is the ability of progenitor cells to differentiate into a few cell types. It is a degree of potency. Examples of oligopotent stem cells are the lymphoid or myeloid stem cells. A lymphoid cell specifically, can give rise to various blood cells such as B and T cells, however, not to a different blood cell type like a red blood cell. Examples of progenitor cells are vascular stem cells that have the capacity to become both endothelial or smooth muscle cells.
In cell biology, a unipotent cell is the concept that one stem cell has the capacity to differentiate into only one cell type. It is currently unclear if true unipotent stem cells exist. Hepatoblasts, which differentiate into hepatocytes (which constitute most of the liver) or cholangiocytes (epithelial cells of the bile duct), are bipotent. A close synonym for unipotent cell is precursor cell.
See original here:
Cell potency - Wikipedia
- Induced Pluripotent Stem Cells (iPSCs) Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News - July 7th, 2020
- In Vitro Toxicology Testing Market to Exhibit Rapid Surge in Consumption in the COVID-19 Crisis 2024 - 3rd Watch News - July 4th, 2020
- Global Stem Cells Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty - June 30th, 2020
- 2020-2024 Global Regenerative Medicine Market with Impact Analysis of COVID-19, Production, Revenue, Demand & Applications - Apsters News - June 30th, 2020
- Stem Cell Therapy Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2020 2025 - Owned - June 29th, 2020
- Citius Receives FDA Response on Pre-Investigational New Drug (PIND) Application for its Induced Mesenchymal Stem Cells (iMSCs) to Treat Acute... - June 27th, 2020
- Induced Pluripotent Stem Cells Market 2020 Global Industry ... - June 20th, 2020
- Induced Pluripotent Stem Cells Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty - June 19th, 2020
- Stem Cell Manufacturing Market Share, Size, Trends 2020- Segments worth Observing Aiding Growth Factors | Merck Group, Becton, Dickinson And Company.... - June 19th, 2020
- Janus-Faced PCL2? Alzheimer's Risk Protein Toggles TREM2 and TLR Pathways - Alzforum - June 13th, 2020
- Here's Why Fate Therapeutics Rose 18.4% in May - The Motley Fool - June 10th, 2020
- Evera, A Harvard Consumer Biotech Company, Brings Stem Cell Banking To You - Forbes - June 10th, 2020
- Nanion Technologies and Nexel Partner to Open a New Reference Demonstration Laboratory in South Korea - Labmate Online - June 10th, 2020
- Induced Pluripotent Stem Cells Market Growth Dynamics ... - June 7th, 2020
- Generation of self-organized sensory ganglion organoids and retinal ganglion cells from fibroblasts - Science Advances - May 30th, 2020
- Hesperos Human-on-a-Chip System Used to Model Preclinical Stages of Alzheimer's Disease and Mild Cognitive Impairment - Business Wire - May 30th, 2020
- AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -... - May 30th, 2020
- In Vitro Toxicology Testing Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario - Cole of Duty - May 30th, 2020
- Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation - SMA News Today - May 25th, 2020
- Stem Cell and Regenerative Medicine Market is Expected to Garner USD 14745.7 Million by The End of 2024 By Recording a CAGR of 4.8% (Impact Analysis... - May 20th, 2020
- Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020 - May 16th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 16th, 2020
- Induced Pluripotent Stem Cells Market 2020: Growing Tends ... - May 16th, 2020
- Cell Therapy Shows Promise in Parkinson's - MedPage Today - May 14th, 2020
- Induced Pluripotent Stem Cells Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual... - May 14th, 2020
- Novel CAR NK-cell technology could lead to new treatments for lupus, other incurable diseases - Stockhouse - May 14th, 2020
- 2020 Insights on the Worldwide Induced Pluripotent Stem Cell Industry - ResearchAndMarkets.com - Business Wire - May 12th, 2020
- Cell and Gene Therapy Catapult links with Japan's CiRA Foundation - PharmaTimes - May 12th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty - May 9th, 2020
- Induced Pluripotent Stem Cells Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026 - Weekly Wall - May 9th, 2020
- Mogrify strikes deal with US biopharma Sangamo Therapeutics - Cambridge Independent - April 28th, 2020
- How could Covid-19 and the body's immune response affect the brain? - MIT News - April 28th, 2020
- Induced Pluripotent Stem Cells Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 28th, 2020
- FDA Expediting Accelerated Development of Novel Therapies for COVID-19 - Yahoo Finance - April 28th, 2020
- GLOBAL TOOTH REGENERATION MARKET: INDUSTRY ANALYSIS AND FORECAST (2020-2027) - MR Invasion - April 28th, 2020
- Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - Yahoo Finance - April 26th, 2020
- Induced pluripotent stem cells and CRISPR reversed diabetes in mice - Drug Target Review - April 24th, 2020
- Reversing diabetes with CRISPR and patient-derived stem cells - FierceBiotech - April 24th, 2020
- The integrated stress response: From mechanism to disease - Science Magazine - April 24th, 2020
- Diabetes reversed in mice with genetically edited stem cells derived from patients - Washington University School of Medicine in St. Louis - April 23rd, 2020
- Business News: Induced Pluripotent Stem Cells Market Growth, Analysis and Forecast 2020 to 2025 | BlueRock Therapeutics, Corning Life Sciences, EMD... - April 23rd, 2020
- Stem Cell Therapy Market: Industry Size, Market Status, Influencing Factors, Competition, Outlook & Forecasts to 2027 - Cole of Duty - April 23rd, 2020
- Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine - April 21st, 2020
- Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 - WhaTech Technology and Markets News - April 21st, 2020
- Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com - April 15th, 2020
- Lung epithelium model being tested as a platform for COVID-19 research - Drug Target Review - April 11th, 2020
- Fate Therapeutics' IO Collaboration with Janssen Could Yield Company $3 Billion - Clinical OMICs News - April 11th, 2020
- Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 - Science In Me - April 9th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Industry Overview on Global Size, Share, Future Trends, Segmentation, Demands, and Top Players... - April 9th, 2020
- Evotec Makes Move into Gene Therapy with Takeda... - Labiotech.eu - April 9th, 2020
- Induced Pluripotent Stem Cell Research Pros And Cons ... - April 2nd, 2020
- Evotec Expands Its IPSC-Based Cell Therapy Platform Evocells Through Licensing Agreement with panCella - Benzinga - April 2nd, 2020
- Citius Signs Option With Novellus To License Novel Stem-Cell Therapy For ARDS - Nasdaq - April 2nd, 2020
- Anti-IL-6 Monoclonal Antibodies as Antiarrhythmic Treatment for HF - The Cardiology Advisor - April 2nd, 2020
- A New NK Cell-based Immunotherapy For Cancer Treatment - Health News Today - March 24th, 2020
- Coriell Institute for Medical Research Awarded $8.6 Million Biobanking Contract from National Institute on Aging - Newswise - March 18th, 2020
- Stem cells to help the heart - Science Magazine - March 12th, 2020
- Induced Pluripotent Stem Cells Market Expected to Witness the Highest Growth 202 - ITResearchBrief.com - March 12th, 2020
- SpaceX Dragon cargo ship, the last to be caught by robot arm, arrives at space station - Space.com - March 11th, 2020
- Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS | DNA RNA and Cells | News Channels - PipelineReview.com - March 11th, 2020
- NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space - Business Wire - March 9th, 2020
- Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government - March 9th, 2020
- Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible - Patheos - March 6th, 2020
- Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise - March 4th, 2020
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today - March 4th, 2020
- SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | - SpaceCoastDaily.com - February 29th, 2020
- The European Bank of Induced Pluripotent Stem Cells: Five Years of Progress - Technology Networks - February 28th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - PR Web - February 26th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Global Industry Size, Demand, Growth & Development, Trends, Insights and Forecast until... - February 25th, 2020
- Improving shoes, showers, 3D printing: research launching to the Space Station - Space Daily - February 21st, 2020
- Argentinian cultured meat supplier on its 'all-in-one' cell line: 'We offer cells that can grow fast and reduce costs' - FoodNavigator-Latam - February 20th, 2020
- Building a 'doomsday vault' to save the kangaroo and koala from extinction - CNET - February 19th, 2020
- Surge in the Adoption of Stem Cell-Derived Cells to Fuel the Growth of the Stem Cell-Derived Cells Market Through the Assessment Period 2019 2029 -... - February 17th, 2020
- Global Induced Pluripotent Stem Cells Market to Achieve more Profitability Ratio between 2020-2025 - Chronicle 99 - February 16th, 2020
- Cell-based meat in focus: In conversation with Meatable, Finless Foods, New Age Meats - FoodNavigator-USA.com - February 11th, 2020
- Research could be step toward lab-grown eggs and sperm to treat... - ScienceBlog.com - February 10th, 2020
- First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News - February 10th, 2020
- Chromatin accessibility analysis reveals regulatory dynamics of developing human retina and hiPSC-derived retinal organoids - Science Advances - February 10th, 2020
- AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other... - February 4th, 2020